Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Author:

Vogelbaum Michael A1ORCID,Brown Paul D2ORCID,Messersmith Hans3ORCID,Brastianos Priscilla K4ORCID,Burri Stuart5,Cahill Dan4,Dunn Ian F6,Gaspar Laurie E78,Gatson Na Tosha N910ORCID,Gondi Vinai11,Jordan Justin T4ORCID,Lassman Andrew B12ORCID,Maues Julia13ORCID,Mohile Nimish14,Redjal Navid15ORCID,Stevens Glen16ORCID,Sulman Erik17ORCID,van den Bent Martin18ORCID,Wallace H James19ORCID,Weinberg Jeffrey S20,Zadeh Gelareh21,Schiff David22ORCID

Affiliation:

1. Moffit Cancer Center, Tampa, Florida, USA

2. Mayo Clinic Cancer Center, Rochester, Minnesota, USA

3. American Society of Clinical Oncology ASCO, Alexandria, Virginia, USA

4. Massachusetts General Hospital, Boston, Massachusetts, USA

5. Levine Cancer Institute at Atrium Health, Charlotte, North Carolina, USA

6. Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, Oklahoma, USA

7. University of Colorado School of Medicine, Aurora, Colorado, USA

8. University of Texas MD Anderson Cancer Center Northern Colorado, Greeley, Colorado, USA

9. Banner MD Anderson Cancer Center, Phoenix, Arizona, USA

10. Geisinger Neuroscience Institute, Danville, Pennsylvania, USA

11. Northwestern Medicine Cancer Center Warrenville and Proton Center, Warrenville, Illinois, USA

12. Columbia University Irving Medical Center, New York, New York, USA

13. Georgetown Breast Cancer Advocates, Washington, DC, USA

14. University of Rochester Medical Center, Rochester, New York, USA

15. Capital Health Medical Center – Hopewell Campus, Princeton, New Jersey, USA

16. Cleveland Clinic, Cleveland, Ohio, USA

17. NYU Langone Health, New York, New York, USA

18. Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands

19. University of Vermont, Burlington, Vermont, USA

20. University of Texas MD Anderson Cancer Center, Houston, Texas, USA

21. University of Toronto, Toronto, Ontario, Canada

22. University of Virginia Medical Center, Charlottesville, Virginia, USA

Abstract

Abstract Purpose To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a systematic review of the literature. Results Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. Recommendations Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non–small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3